Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
Year: 2019
Type: article
Authors: Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Amir T. Fathi, Olga Frankfurt, Andre C. Schuh, Hartmut Döhner, Giovanni Martinelli, Emmanuel Raffoux, Peter Tan, Amer Zeidan, Stéphane de Botton, Hagop M. Kantarjian, Richard M. Stone, Du Lam, Xiwei Wang, Jing Gong, Stephanie M. Kapsalis, Denice Hickman, Vickie Zhang, Thomas Winkler, Scott Daigle, Paresh Vyas
Institutions: The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, Northwestern University, Princess Margaret Cancer Centre, University Hospital Ulm, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Hôpital Saint-Louis, Royal Perth Hospital, Yale Cancer Center, Institut Gustave Roussy, Dana-Farber Cancer Institute, Celgene (United States), Agios Pharmaceuticals (United States), University of Oxford
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2970425807